Form 4: BioXcel Therapeutics Director David Mack Acquires Shares Through Vesting of Restricted Stock Units
SEC Form 4 Filing
BioXcel Therapeutics director David Mack acquired 27,089 shares of common stock through the vesting of restricted stock units.
Summary
- David Mack, a director at BioXcel Therapeutics, acquired 27,089 shares of common stock on December 31, 2024.
- This acquisition resulted from the vesting of restricted stock units (RSUs).
- The director now beneficially owns 54,178 shares of common stock.
- The RSUs were part of a grant of 325,077 RSUs awarded on November 21, 2024, vesting in twelve equal monthly installments.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to slightly positive as it aligns management with shareholder interests.
Positives
- The vesting of RSUs indicates continued service and commitment from the director.
- The acquisition increases the director's stake in the company, aligning his interests with shareholders.
Future Outlook
The remaining RSUs will continue to vest monthly, subject to the director's continued service.
Industry Context
This is a routine transaction related to executive compensation and is common in publicly traded companies.
Comparison to Industry Standards
- The vesting of restricted stock units is a standard practice for compensating directors and executives in the biotechnology industry.
- Many companies, such as Amgen, Gilead Sciences, and Regeneron, use similar equity-based compensation plans to align management interests with shareholder value.
- The vesting schedule of monthly installments is also a common approach to incentivize long-term commitment.
Stakeholder Impact
- The transaction increases the director's stake in the company, aligning his interests with shareholders.
- The vesting of RSUs is part of the director's compensation package and does not have a direct impact on other stakeholders.
Next Steps
- The remaining RSUs will continue to vest monthly, subject to the director's continued service.
Key Dates
| Date | Description |
|---|---|
| 2024-11-21 | Date of grant of 325,077 Restricted Stock Units to David Mack. |
| 2024-12-31 | Date of transaction where 27,089 Restricted Stock Units vested, resulting in the acquisition of 27,089 shares of common stock. |
| 2024-11-30 | First vesting date of the Restricted Stock Units. |
| 2025-01-03 | Date of filing of the SEC Form 4. |
Keywords
BioXcel Therapeutics, BTAI, David Mack, Restricted Stock Units, RSU, Director, Share Acquisition, Vesting, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.